- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01241409
A Bioequivalence Study of 2 Formulations of Rabeprazole Sodium and Evaluation of the Effect of Food on Rabeprazole Sodium in Healthy Adult Volunteers
October 28, 2012 updated by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pivotal Study to Assess the Bioequivalence of the To-be-Marketed Sprinkle Capsule Formulation and the Phase 3 Sprinkle Capsule Formulation of Rabeprazole Sodium in Fasted Condition and to Assess the Effect of Food on the To-be-Marketed Formulation in Healthy Adult Subjects
The purpose of the study is to evaluate and compare the pharmacokinetics (blood levels) of 2 sprinkle capsule formulations of rabeprazole sodium when administered without food to healthy volunteers.
In addition, the pharmacokinetics of 1 formulation of rabeprazole sodium will be evaluated when administered with food to healthy volunteers.
Study Overview
Status
Completed
Conditions
Detailed Description
This is a randomized (study drug assigned by chance), open-label (the volunteer will know the treatment/drug they are taking), single-dose study of 2 formulations of rabeprazole sodium in healthy adult volunteers.
Rabeprazole sodium is a drug used to treat patients with Gastroesophageal Reflux Disease (GERD), a condition where the esophagus (tube from throat to stomach) becomes irritated or inflamed as a result of acid that backs up into the esophagus from the stomach.
All volunteers will receive 3 doses of study drug; each dose of study drug will be separated by at least 7 days.
Blood samples will be collected from volunteers during the study to measure the concentration of study drug.
Approximately 78 healthy volunteers will be enrolled and will participate in the study for a total of approximately 39 days.
During the study, the healthy volunteer will make a total of approximately 4 visits to the study center.
The 4 visits will include an initial screening visit and 3 visits to receive study drug.
Volunteers will be required to stay at the study center for at least 12 hours before study drug administration and up to approximately 24 hours after study drug administration to have study procedures performed and blood samples collected to measure the concentrations of rabeprazole and its thioether metabolite (a substance produced when rabeprazole is metabolized in the body) in the plasma (ie, the clear liquid portion of blood).
Volunteers will be monitored for safety throughout the study.
Healthy volunteers will receive a single dose of study drug in 3 treatment periods.
In each treatment period, healthy volunteers will receive one 10 mg capsule of rabeprazole sodium or two 5 mg capsules of rabeprazole sodium.
The contents of study drug capsules will be sprinkled on 1 tablespoon of applesauce and administered orally (by mouth) to healthy volunteers in the morning who have fasted (not eaten) overnight and to those who have eaten a standardized breakfast.
Study Type
Interventional
Enrollment (Actual)
78
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have a body mass index (BMI) between 18 and 30 kg/m² (inclusive), and body weight not less than 50 kg
- Women must be postmenopausal (no spontaneous menses for at least 2 years), surgically sterile, abstinent, or, if of childbearing potential and sexually active, be practicing an effective method of birth control before entry and throughout the study
- Women must have a negative serum beta-human chorionic gonadotropin (hCG) pregnancy test at screening and a negative urine pregnancy test on Day -1 of each treatment period
- Men must agree to use an adequate contraception method as deemed appropriate by the investigator
- Have normal blood pressure between 90 and 140 mmHg systolic and <=90 mmHg diastolic
- Exclusion Criteria:
- Currently have, or have a history of medical illness considered by the Investigator to be clinically significant or any other illness that the investigator considers should exclude the volunteer or that could interfere with the interpretation of the study results
- Have clinically significant abnormal values for hematology, clinical chemistry or urinalysis at screening as deemed appropriate by the investigator
- Have clinically significant abnormal physical examination, vital signs or 12 lead electrocardiogram (ECG) at screening as deemed appropriate by the investigator
- Have a history of drug or alcohol abuse within the past 1 year
- Have a history of smoking or use of nicotine-containing substances within the previous 2 months
- Have had major or traumatic surgery within 12 weeks before screening or preplanned surgery or procedures that would interfere with the conduct of the study
- Known allergy to the study drug or any of the excipients of the formulation
- Known allergy to heparin or history of heparin-induced thrombocytopenia
- Use of any concomitant therapy which are drug metabolizing enzyme (cytochrome P450) inducers or inhibitors within 6 weeks before study entry and during the entire study
- Use of any prescription or nonprescription medication (including vitamins and herbal supplements), except for paracetamol, hormonal contraceptives and hormonal replacement therapy, within 14 days before the first dose of the study drug is scheduled
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment sequence ABC
|
One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
|
Experimental: Treatment sequence ACB
|
One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
|
Experimental: Treatment sequence BAC
|
One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
|
Experimental: Treatment sequence BCA
|
One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
|
Experimental: Treatment sequence CAB
|
One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
|
Experimental: Treatment sequence CBA
|
One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast.
After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma concentrations of rabeprazole sodium
Time Frame: Up to 16 hours after each study drug administration
|
Up to 16 hours after each study drug administration
|
Plasma concentrations of thioether metabolite
Time Frame: Up to 16 hours after each study drug administration
|
Up to 16 hours after each study drug administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number of participants with adverse events as a measure of safety and tolerability
Time Frame: Up to approximately 39 days
|
Up to approximately 39 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Clinical Trial, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2010
Primary Completion (Actual)
December 1, 2010
Study Completion (Actual)
December 1, 2010
Study Registration Dates
First Submitted
October 21, 2010
First Submitted That Met QC Criteria
November 12, 2010
First Posted (Estimate)
November 16, 2010
Study Record Updates
Last Update Posted (Estimate)
October 30, 2012
Last Update Submitted That Met QC Criteria
October 28, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR014830
- RABGRD1007 (Other Identifier: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Rabeprazole sodium: Treatment A
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Janssen Cilag S.A.S.Completed
-
Eisai Co., Ltd.Completed
-
Eisai Inc.CompletedSymptomatic Gastroesophageal Reflux Disease (sGERD)United States
-
Janssen Research & Development, LLCEisai Inc.CompletedGastroesophageal Reflux Disease (GERD)United States, Poland, United Kingdom, Belgium, Brazil
-
Yungjin Pharm. Co., Ltd.Seoul National University HospitalCompletedGastroesophageal Reflux DiseaseKorea, Republic of
-
Jordan Collaborating Cardiology GroupCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...Eisai Inc.CompletedGastroesophageal RefluxUnited States, Belgium, Israel, Poland, Australia, Netherlands, South Africa, Hungary, Bulgaria, Denmark
-
Zeria PharmaceuticalCompleted
-
Medical College of WisconsinEisai Inc.; Ortho-McNeil, Inc.Completed